Sir,
We would like to thank Zanini et al (2010) for their critical discussion of our data from a randomised phase II trial in locally advanced pancreatic cancer (LAPC) that was recently published in this journal (Wilkowski et al, 2009).
During the previous years, LAPC has been increasingly recognised as a separate disease entity in malignant pancreatic disorders. With the use of systemic gemcitabine-based chemotherapy, LAPC has a favourable survival prognosis compared with metastatic pancreatic cancer; however, the value of chemoradiotherapy still remains controversial in this stage of disease (Chauffert et al, 2008). We fully agree with Zanini et al that a unique, internationally standardised and accepted definition of LAPC is not yet established to date, and that such an approach is strongly recommend for future clinical trials in LAPC. Currently, different study groups still apply individual definitions for LAPC (Chauffert et al, 2008; Crane et al, 2009) and this definition probably is still mostly influenced by the definition of ‘resectability’ of the involved surgeon. A first step for the formulation of standardised criteria defining the respectability status in pancreatic cancer (e.g., ‘resectable’ vs ‘borderline resectable’ vs ‘unresectable’) is included in the current version of the NCCN guidelines for pancreatic adenocarcinoma (http://www.nccn.org, V.I.2009).
At the time when our phase II study was designed in 2001, the criteria for defining LAPC included in the study protocol were a first attempt to standardise the LAPC definition in the setting of a prospective multi-centre clinical trial. However, the authors are fully aware of the limitations of such an approach, as critically formulated by Zanini et al. In fact, much more future research will be necessary in order to better characterise LAPC clinically and biologically. Besides, currently – as recently reported in a study by Morak et al – the classification of a tumour as LAPC may still depend on the diagnostic possibilities and on the experience of a clinical institution (Morak et al, 2009).
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol 19: 1592–1599
Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, Wolff RA, Willett CG (2009) Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 27: 4096–4102
Morak MJ, Hermans JJ, Smeenk HG, Renders WM, Nuyttens JJ, Kazemier G, van Eijck CH (2009) Staging for locally advanced pancreatic cancer. Eur J Surg Oncol 35: 963–968
Wilkowski R, Boeck S, Ostermaier S, Sauer R, Herbst M, Fietkau R, Flentje M, Miethe S, Boettcher HD, Scholten T, Bruns CJ, Rau HG, Hinke A, Heinemann V (2009) Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study. Br J Cancer 101: 1853–1859
Zanini N, Masetti M, Jovine E . The definition of locally advanced pancreatic cancer. Br J Cancer 2010 102: 1306–1307
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Boeck, S., Heinemann, V. Reply to: The definition of locally advanced pancreatic cancer. Br J Cancer 102, 1308 (2010). https://doi.org/10.1038/sj.bjc.6605631
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6605631